| Literature DB >> 25496727 |
Marthe-Elise Ngo-Matip1, Constant Anatole Pieme, Marcel Azabji-Kenfack, Prosper Cabral Nya Biapa, Nkenfack Germaine, Englert Heike, Bruno Moukette Moukette, Korosky Emmanuel, Stefanini Philippe, Carl Moses Mbofung, Jeanne Yonkeu Ngogang.
Abstract
BACKGROUND: Cardiovascular diseases (CVD) and metabolic alterations are among the majors public health concern that have been reported in people living with HIV infections. Factors contributing to cardio metabolic syndrome in HIV include body fat distribution, dyslipidemia, insulin resistance, cardiovascular dysfunction and inflammation. The aim of the study was to determine the effect of Spirulina platensis (Cyanobacteriaceae) supplementation versus local diet on lipid profile in HIV-infected antiretroviral-naive patients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25496727 PMCID: PMC4290440 DOI: 10.1186/1476-511X-13-191
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Composition of freeze-dried powder of intake in our study
| Composition | g/100 of dry mass (%) | Energetic values (kilo calories) |
|---|---|---|
|
| ||
|
| 61.81 | 258.36 |
|
| 16.06 | 144.54 |
|
| 12.36 | 51.66 |
|
| 9.77 | |
|
| 88.75 | |
|
| 02.26 | |
|
| ||
|
| 0.28 | |
|
| 0.93 | |
|
| 14.40 | |
|
| 1.96 | |
|
| 90.75 | |
|
| 21.98 | |
|
| 7.81 |
The analysis of the freeze-dried spirulina powder sample obtained from the Institute of Medical and Medicinal Plants (IMMP) (Yaounde-Cameroon).
Figure 1Flow chart describing progress of participants through the supplementation trial.
Micronutrients intake of the HIV-ARV naïve population before and after spirulina supplementation
| Variables | Ctrol/Spi | Period | Patients received local balance diet | Patients received spirulina combined with a local balance diet |
|
|---|---|---|---|---|---|
|
| 87/82 | T0 | 60.51 ± 16.39 | 48.03 ± 8.85 | <0.001 |
| 79/80 | T6 | 62.61 ± 14.12 | 66.03 ± 9.3 | 0.10 | |
| 66/79 | T12 | 60.28 ± 13.52 | 72.77 ± 7.3 | <0.001 | |
|
| 87/82 | T0 | 12.03 ± 1.12 | 12.85 ± 2.64 | <0.01 |
| 79/80 | T6 | 11.86 ± 1.30 | 16.04 ± 1.20 | <0.001 | |
| 66/79 | T12 | 11.80 ± 1.14 | 14.67 ± 3.75 | <0.001 | |
|
| 87/82 | T0 | 81 ± 6.35 | 70 ± 4.50 | <0.001 |
| 79/80 | T6 | 6.36 ± 2.67 | 5.79 ± 1.70 | 0.15 | |
| 66/79 | T12 | 4.28 ± 3.16 | 6.92 ± 1.53 | <0.001 | |
|
| 87/82 | T0 | 487.09 ± 194.58 | 666.18 ± 680.75 | <0.02 |
| 80/79 | T6 | 509.60 ± 248.11 | 1339.90 ± 303.37 | <0.001 | |
| 79/66 | T12 | 510.87 ± 220.48 | 943.85 ± 308.39 | <0.001 | |
|
| 87/82 | T0 | 1148,48 ± 2,00 | 766,57 ± 2,40 | <0.01 |
| 79/80 | T6 | 2306 ± 733.53 | 4555 ± 798.93 | <0.001 | |
| 66/79 | T12 | 2593 ± 112.44 | 3241 ± 709.83 | <0.001 | |
|
| 87/82 | T0 | 223.23 ± 114.60 | 250.10 ± 91.99 | 0.11 |
| 79/80 | T6 | 231.61 ± 88.78 | 428.44 ± 78.5 | <0.001 | |
| 66/79 | T12 | 251.21 ± 143.00 | 288.00 ± 80.70 | 0.07 | |
|
| 87/82 | T0 | 379.37 ± 83.24 | 464.54 ± 160,74 | <0.001 |
| 79/80 | T6 | 402.77 ± 66.29 | 216.32 ± 100.50 | <0.001 | |
| 66/79 | T12 | 413.88 ± 56.05 | 292.67 ± 55.54 | <0.001 |
Mean values ± SD, Ctrl: Control, Spi: Spirulina group T0: initial period, T6: Six months, T12: Twelve months Mean values ± SD. p < 0.01: Significant difference between the group.
Baseline of demographic and clinical characteristics of patients during the trial
| Variables | Ctrl/Spi | Period | Patients received local balance diet | Patients received spirulina combined with a local balance diet |
|
|---|---|---|---|---|---|
|
| 87/82 | T0 | 35.43 ± 10.04 | 36.01 ± 9.44 | 0,58 |
|
| |||||
|
| 87/82 | T0 | 64.5% (56) | 69.8% (60) | 0.06 |
|
| 35.6% (31) | 25.6% (22) | |||
|
| 87/82 | T0 | 26.02 ± 4.97 | 25.29 ± 4.54 | 0.33 |
| 79/80 | T6 | 25.18 ± 6.41 | 25.41 ± 4.98 | 0.80 | |
| 66/79 | T12 | 22.18 ± 1.07 | 23.26 ± 6.53 | 0.44 | |
|
| 87/82 | T0 | 115 ± 53,70 | 105.89 ± 25.91 | 0.159 |
| 79/80 | T6 | 105.00 ± 30.76 | 103.14 ± 15.93 | 0.65 | |
| 66/79 | T12 | 113.77 ± 61,85 | 95.35 ± 9.63 | <0,001 | |
|
| 14/169 | To | 11.9% | 11.9% | |
| 10/156 | T6 | 11.9% | 5.6% | ||
| 7/145 | T12 | 4.4% | 4.4% | ||
|
| 5/169 | To | 3% | 4.5% | |
| 5/169 | T6 | 3% | 4.5% | ||
| 6/169 | T12 | 1.4% | 3% |
Ctrl: Control, Spi: Spirulina group, T0: initial period, T6: Six months, T12: Twelve months, p< 0.01: Significant difference between the group.
Change in lipid profile during the six months of intervention and the follow up in each group
| Variables | Ctrl/Spi | Period | Patients received local balance diet | Patients received spirulina combined with a local balance diet |
|
|---|---|---|---|---|---|
|
| 87/82 | T0 | 194.8 ± 80.1 | 228.7 ± 96.8 | 0.17 |
| 79/80 | T6 | 216.8 ± 109.4 | 143.3 ± 45.4 | <0.001 | |
| 66/79 | T12 | 234.9 ± 101.8 | 141.4 ± 40.1 | <0001 | |
|
| 87/82 | T0 | 53.6 ± 18.4 | 48.0 ± 21.1 | 0.71 |
| 79/80 | T6 | 49.9 ± 21.6 | 83.2 ± 39.7 | <0. 001 | |
| 88/79 | T12 | 57.3 ± 27.0 | 100.9 ± 28.7 | <0.001 | |
|
| 87/82 | T0 | 120.12 ± 75.8 | 127.0 ± 92.2 | 0.60 |
| 79/80 | T6 | 138.3 ± 105.8 | 44.5 ± 33.0 | <0.001 | |
| 66/79 | T12 | 146.3 ± 97.8 | 29.3 ± 16.8 | <0.001 | |
|
| 87/82 | T0 | 117.6 ± 76.8 | 206.9 ± 122.7 | <0.0001 |
| 79/80 | T6 | 150.4 ± 97.5 | 139.8 ± 64.2 | 0.44 | |
| 66/79 | T12 | 167.1 ± 124.8 | 123.5 ± 44.6 | <0.01 | |
|
| 87/82 | T0 | 3.6 ± 4.3 | 4.7 ± 4.6 | 0.21 |
| 79/80 | T6 | 4.34 ± 5.1 | 1.7 ± 1.1 | 0.64 | |
| 66/79 | T12 | 4.1 ± 3.0 | 1.4 ± 1.4 | <0.0001 | |
|
| 87/82 | T0 | 2.2 ± 4.1 | 2.6 ± 4.3 | 0.26 |
| 79/80 | T6 | 2.8 ± 4.89 | 0.53 ± 0.84 | 0.21 | |
| 66/79 | T12 | 2.5 ± 3.6 | 0.3 ± 0.6 | <0.0001 |
Mean values ± SD.
Ctrl: Control, Spi: Spirulina group; TC: HDL-C and LDL-C: HDL-C ratios were used to calculate the atherogenicity index. TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides, P < 0.01: Significant difference between the group.
Figure 2Concentration of triglycerides levels of the two groups of patients during the trial.
Figure 3Concentration of total cholesterol levels of the two groups during the trial.
Figure 4Concentration of HDL-Cholesterol levels of the two groups during the trial.
Figure 5Concentration of LDL cholesterol of the two groups during the trial.
Figure 6Concentration of artherogenic index of the patients in the two groups during the trial.